MaxCyte to acquire Akron Bio, raises 2026 revenue guidance to at least $34.5 million

MaxCyte said on November 10, 2026 that it entered a Securities Purchase Agreement on November 9, 2026 to acquire all of the outstanding equity interests of Akron BioProducts LLC, through sellers Ohio TopCo LP and Arcline Capital Partners A LP, affiliates of Arcline Investment Management.¹ The deal is structured as $105.0 million in cash at closing, 20,639,733 shares of MaxCyte common stock, and $20.0 million in guaranteed deferred cash payments split into $10.0 million installments due on the first business day of 2028 and 2029.¹ Closing is subject to customary conditions including Hart-Scott-Rodino antitrust clearance and Nasdaq listing approval for the stock consideration, is not conditioned on financing or shareholder approval, and is expected to occur before the end of 2026.¹ The company described Akron as a leading supplier of GMP-grade reagents and ancillary materials, expanding its offering across cell therapy manufacturing and nearly doubling revenue.¹

On the commercial side, MaxCyte reported total revenue of $10.2 million in the third quarter of 2026, an increase of 49% over the third quarter of 2025, with core business revenue of $8.2 million, up 27%, and Strategic Platform License (SPL) Program-related revenue of $2.0 million, versus $0.4 million a year earlier.¹ The company said total SPL agreements numbered 28 as of September 30, 2026, including 13 programs currently in the clinic and one commercial program.¹

MaxCyte raised its outlook, saying excluding the Akron acquisition, full year revenue is now expected to be at least $34.5 million, consisting of core revenue of approximately $28 million and SPL Program-related revenue of at least $6.5 million, including about $4 million from milestones and at least $2.5 million from commercial royalties.¹ The company also disclosed cash of $132.7 million as of September 30, 2026,¹ and said that assuming the Akron deal closes, it expects approximately $40.0 to $45.0 million in total cash, cash equivalents and investments at year end, reflecting the $105.0 million cash payment, deal expenses, and $22.0 million drawn under its MidCap Financial credit facility.¹